Hong Kong–listed 3D Medicines Inc. (stock code: 01244) filed its Monthly Return for September 2026, reporting no changes to its share capital structure.

The company’s authorised share capital closed the month at 500.00 million ordinary shares with a par value of HKD 0.001 each, unchanged from August. Issued shares also remained flat at 258.18 million, and the firm continued to hold zero treasury shares. Consequently, total issued share capital stood at HKD 0.26 million.

3D Medicines confirmed that its public float exceeded the Main Board’s minimum 25 percent requirement as at 30 September 2026.

Under the Share Option Scheme approved on 26 June 2023, 12.80 million options were outstanding at month-end, equal to a prospective dilution of roughly 4.96 percent if fully exercised. No options were exercised in September, and no new shares were issued or cancelled; there were also no warrants, convertibles, or other equity-linked instruments outstanding.

Director Gong Zhaolong certified that all regulatory obligations associated with the company’s securities were duly satisfied during the reporting period.